Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations
Not yet recruiting
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3
To assess the efficacy and safety of Aumolertinib plus chemotherapy versus Aumolertinib alone
as first-line treatment in locally advanced or metastatic non-small cell lung cancer (NSCLC)
with sensitizing epidermal growth factor receptor mutations (EGFRm+).
To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations
Completed
EQRx, Inc.
Phase 1
This is an open-label and uncontrolled study to evaluate the comparative PK of EQ143
following oral single dose administration in adult healthy volunteers different racial and
ethnic populations.
A total of one (1) single dose cohort is planned at 110 mg of EQ143. EQ143 is an approved
therapy in China at the 110 mg dose for the treatment of patients with Epidermal Growth
Factor Receptor (EGFR) T790Mmutation-positive, metastatic non-small cell lung cancer (NSCLC),
who have progressed during or after EGFR tyrosine kinase inhibitor (TKI) therapy.
A total of 45 (15 Caucasian, 8 Black/African American and 7 Hispanic/Latino, and 15 ethnic
Chinese)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
